著書論文等- 石田 孝宣 -
表示方法: 表示形式: 表示順:
[]:著書 []:論文 []:総説・解説記事
件数:871件
[2019]
1.[] Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells..[Clinical & experimental metastasis,36(5),(2019),423-432]Iwabuchi E, Miki Y, Onodera Y, Shibahara Y, Takagi K, Suzuki T, Ishida T, Sasano H
10.1007/s10585-019-09981-2
http://www.ncbi.nlm.nih.gov/pubmed/31222613
2.[] Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry..[Annals of surgical oncology,26(8),(2019),2475-2485]Miyashita M, Niikura N, Kumamaru H, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Tsuda H, Nakamura S, Tokuda Y
10.1245/s10434-019-07453-1
http://www.ncbi.nlm.nih.gov/pubmed/31102090
3.[] The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer..[Oncotarget,10(47),(2019),4907-4918]Iida M, Nakamura M, Tokuda E, Toyosawa D, Niwa T, Ohuchi N, Ishida T, Hayashi SI
10.18632/oncotarget.27127
http://www.ncbi.nlm.nih.gov/pubmed/31448056
4.[] The significance of lipid accumulation in breast carcinoma cells through perilipin 2 and its clinicopathological significance..[Pathology international,69(8),(2019),463-471]Kuniyoshi S, Miki Y, Sasaki A, Iwabuchi E, Ono K, Onodera Y, Hirakawa H, Ishida T, Yoshimi N, Sasano H
10.1111/pin.12831
http://www.ncbi.nlm.nih.gov/pubmed/31273897
5.[] Site-Specific Labeling of F-18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O-2-[<sup>18</sup>F]Fluoroethyl-L-Tyrosine: [<sup>18</sup>F]FET-HER2 Affibody Molecule..[Molecular imaging and biology,21(3),(2019),529-537]Yanai A, Harada R, Iwata R, Yoshikawa T, Ishikawa Y, Furumoto S, Ishida T, Yanai K
10.1007/s11307-018-1266-z
http://www.ncbi.nlm.nih.gov/pubmed/30112727
6.[] Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer..[Breast cancer (Tokyo, Japan),26(3),(2019),272-281]Iida M, Tsuboi K, Niwa T, Ishida T, Hayashi SI
10.1007/s12282-018-0922-0
http://www.ncbi.nlm.nih.gov/pubmed/30328006
7.[] Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma..[Histology and histopathology,(2019),18130-]Sato A, Takagi K, Miki Y, Yoshimura A, Hara M, Ishida T, Sasano H, Suzuki T
10.14670/HH-18-130
http://www.ncbi.nlm.nih.gov/pubmed/31149728
8.[] Reproductive history and breast cancer survival: a prospective patient cohort study in Japan..[Breast cancer (Tokyo, Japan),(2019)]Minami Y, Nishino Y, Kawai M, Tada H, Kanemura S, Miyashita M, Ishida T, Kakugawa Y
10.1007/s12282-019-00972-5
http://www.ncbi.nlm.nih.gov/pubmed/30993643
9.[] Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR<sup>+</sup>/HER2<sup>-</sup> Breast Cancer..[Cancers,11(4),(2019)]Guo Z, Tada H, Kitamura N, Hamada Y, Miyashita M, Harada-Shoji N, Sato A, Hamanaka Y, Tsuboi K, Harada N, Takano-Kasuya M, Okada H, Nakano Y, Ohuchi N, Hayashi SI, Ishida T, Gonda K
10.3390/cancers11040526
http://www.ncbi.nlm.nih.gov/pubmed/31013810
10.[] S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells..[Cellular oncology (Dordrecht),42(1),(2019),67-80]Kikuchi K, McNamara KM, Miki Y, Iwabuchi E, Kanai A, Miyashita M, Ishida T, Sasano H
10.1007/s13402-018-0408-2
http://www.ncbi.nlm.nih.gov/pubmed/30244410
11.[] The 10-Min Holistic Self-Care for Patients with Breast Cancer-Related Lymphedema: Pilot Randomized Controlled Study..[The Tohoku journal of experimental medicine,247(2),(2019),139-147]Arinaga Y, Piller N, Sato F, Ishida T, Ohtake T, Kikuchi K, Sato-Tadano A, Tada H, Miyashita M
10.1620/tjem.247.139
http://www.ncbi.nlm.nih.gov/pubmed/30799328
12.[] Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy..[Breast cancer research and treatment,173(2),(2019),275-288]Guestini F, Ono K, Miyashita M, Ishida T, Ohuchi N, Nakagawa S, Hirakawa H, Tamaki K, Ohi Y, Rai Y, Sagara Y, Sasano H, McNamara KM
10.1007/s10549-018-4985-6
http://www.ncbi.nlm.nih.gov/pubmed/30306430
[2018]
13.[] The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer..[The Journal of pathology,246(3),(2018),379-389]Iwabuchi E, Miki Y, Kanai A, Miyashita M, Kijima G, Hirakawa H, Suzuki T, Ishida T, Sasano H
10.1002/path.5148
http://www.ncbi.nlm.nih.gov/pubmed/30058236
14.[] OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma..[Cancer science,109(10),(2018),3350-3359]Mayama A, Takagi K, Suzuki H, Sato A, Onodera Y, Miki Y, Sakurai M, Watanabe T, Sakamoto K, Yoshida R, Ishida T, Sasano H, Suzuki T
10.1111/cas.13770
http://www.ncbi.nlm.nih.gov/pubmed/30137688
15.[] Effect of the normal mammary differentiation regulator ELF5 upon clinical outcomes of triple negative breast cancers patients.[BREAST CANCER,25(4),(2018),489-496]Omata Fumiya, McNamara Keely May, Suzuki Koyu, Abe Eriko, Hirakawa Hisashi, Ishida Takanori, Ohuchi Noriaki, Sasano Hironobu
10.1007/s12282-018-0842-z
http://www.ncbi.nlm.nih.gov/pubmed/29396764 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000435013300015&DestApp=WOS
16.[] Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis.[CANCER SCIENCE,109(6),(2018),2027-2035]Watanabe Gou, Chiba Natsuko, Nomizu Tadashi, Furuta Akihiko, Sato Kaolu, Miyashita Minoru, Tada Hiroshi, Suzuki Akihiko, Ohuchi Noriaki, Ishida Takanori
10.1111/cas.13595
http://www.ncbi.nlm.nih.gov/pubmed/29601120 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000434351000027&DestApp=WOS
17.[] 乳がんFEC100療法におけるニューロキニン1受容体拮抗薬の費用効果分析の検討.[医薬品相互作用研究,42(2), (2018), 95-102]中川 直人, 渡邊 桂子, 菊地 正史, 石田 孝宣, 木皿 重樹, Lai Leanne
18.[] HER2陽性進行再発乳癌におけるPertuzumab及びT-DM1の使用経験.[東北医学雑誌,130(1), (2018), 131-132]金井 綾子, 佐藤 章子, 多田 寛, 渡部 剛, 宮下 穣, 原田 成美, 濱中 洋平, 飯田 雅史, 小坂 真吉, 谷内 亜衣, 佐藤 未来, 柳垣 美歌, 石田 孝宣
19.[] Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer.[TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE,245(1),(2018),13-19]Yanai Ai, Itoh Masatoshi, Hirakawa Hisashi, Yanai Kazuhiko, Tashiro Manabu, Harada Ryuichi, Yoshikawa Akira, Yamamoto Seiichi, Ohuchi Noriaki, Ishida Takanori
10.1620/tjem.245.13
http://www.ncbi.nlm.nih.gov/pubmed/29731479 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000434105700003&DestApp=WOS
20.[] The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma..[Molecular and cellular endocrinology,466,(2018),31-37]Takagi K, Miki Y, Ishida T, Sasano H, Suzuki T
10.1016/j.mce.2017.09.011
http://www.ncbi.nlm.nih.gov/pubmed/28918115
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [next]
戻るこのページのトップへ
copyright(c)2005 Tohoku University